Krebsforschung made in Tübingen
Exzellenzcluster iFIT

Prof. Dr. Lars Zender
Ärztlicher Direktor der Klinik für Medizinische Onkologie & Pneumologie
Sprecher des iFIT Exzellenzclusters

Lars.Zender@med.uni-tuebingen.de

Auswahl von iFIT-bezogenen Publikationen mit dem höchsten Impact Factor.

• Wolter, K., Zender, L. Therapy-induced senescence — an induced synthetic lethality in liver cancer?. Nat Rev Gastroenterol Hepatol 17, 135–136 (2020). https://doi.org/10.1038/s41575-020-0262-3
• Li, X., Ramadori, P., Pfister, D. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 21, 541–557 (2021). https://doi.org/10.1038/s41568-021-00383-9
• Pfister, D., Núñez, N.G., Pinyol, R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021). https://doi.org/10.1038/s41586-021-03362-0
• Reautschnig, P., Wahn, N., Wettengel, J. et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat Biotechnol 40, 759–768 (2022). https://doi.org/10.1038/s41587-021-01105-0
•  Schwabe, R., Affo, S., Nair, A. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 39, 866-882 (2021). https://doi.org/10.1016/j.ccell.2021.03.012
• Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol. 2020 Feb;72(2):239-249. 10.1016/j.jhep.2019.09.028.
• Zender, L., Artista, L., Moschopoulou, A. et al. MYC determines lineage commitment in kras driven primary liver cancer development. J Hepatol. 2023 Mar 9;S0168-8278(23). 10.1016/j.jhep.2023.02.039
•  Rudalska, R., Harbig, J., Snaebjornsson, M.T. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2, 201–217 (2021). https://doi.org/10.1038/s43018-020-00168-3
• Brenner, E., Schörg, B.F., Ahmetlić, F. et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335 (2020). https://doi.org/10.1038/s41467-020-14987-6
• Hinterleitner, C., Strähle, J., Malenke, E. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 12, 7005 (2021). https://doi.org/10.1038/s41467-021-27303-7   

Prof. Dr. Bernd Pichler
Direktor der Abteilung für Präklinische Bildgebung und Radiopharmazie
Co-Sprecher des iFIT Exzellenzclusters

Bernd.Pichler@med.uni-tuebingen.de

Mehr erfahren

Auswahl von iFIT-bezogenen Publikationen mit dem höchsten Impact Factor.

• Feil S, Stowbur D, Schörg BF, Ehrlichmann W, Reischl G, Kneilling M, Pichler BJ, Feil R. Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice. Circ Res. 2023 Mar 17;132(6):747-750. 10.1161/CIRCRESAHA.122.322296.
• Rudalska, R., Harbig, J., Snaebjornsson, M.T. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2, 201–217 (2021). https://doi.org/10.1038/s43018-020-00168-3.
• Brenner, E., Schörg, B.F., Ahmetlić, F. et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335 (2020). https://doi.org/10.1038/s41467-020-14987-6
• Nording, H., Baron, L., Haberthür, D. et al. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun 12, 3352 (2021). https://doi.org/10.1038/s41467-021-23499-w
• Zekri, L., Vogt, F., Jung, G. et al. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021, Feb 5;13(2):e11902. 10.15252/emmm.201911902.
• Montes-Mojarro, IA., Steinhilber, J., Griessinger, C.M. et al. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. Leukemia 36, 2050–2063 (2022). https://doi.org/10.1038/s41375-022-01617-x
• Marciano S, Ionescu TM, Saw RS, Cheong RY, Kirik D, Maurer A, Pichler BJ, Herfert K. Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2122552119. 10.1073/pnas.2122552119.
• Rammensee, HG., Wiesmüller, KH., Chandran, P.A. et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. j. immunotherapy cancer 7, 307 (2019). https://doi.org/10.1186/s40425-019-0796-5.
• Hoffmann, S., Reck, D., Griessinger, C. et al. Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. Theranostics. 2019 Aug 12;9(20): 5869-5885. 10.7150/thno.33275.
• Schwenk, J., Schörg, B., Kneilling, M. et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo (18)F-FDG-PET. Theranostics. 2020 Jan 1;10(2):925-937. 10.7150/thno.35989 

Prof. Dr. Juliane Walz

Medizinische Direktorin der Abteilung
für Peptidbasierte Immuntherapie
Co-Sprecherin des iFIT Exzellenzclusters

juliane.walz@med.uni-tuebingen.de

Mehr erfahren

Auswahl von iFIT-bezogenen Publikationen mit dem höchsten Impact Factor.

• Nelde, A., Bilich, T., Heitmann, J.S. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74–85 (2021). https://doi.org/10.1038/s41590-020-00808-x
• Bilich T, Roerden M, Maringer Y et al. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discov. 2021 Aug;11(8):1982-1995. (2021). 10.1158/2159-8290.CD-21-0191
• Heitmann, J.S., Bilich, T., Tandler, C. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022). https://doi.org/10.1038/s41586-021-04232-5
• Bauer, J., Köhler, N., Maringer, Y. et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 13, 6401 (2022). https://doi.org/10.1038/s41467-022-33746-3
• Maringer Y, Nelde A, Schroeder SM. et al. Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Science Immunol. 2022 Nov 1:eadd3899 (2022). 10.1126/sciimmunol.add3899
• Naghavian R, Faigle W, Oldrati P. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature. 2023 May 17 (2023). doi: 10.1038/s41586-023-06081-w
• Heitmann JS, Tandler C, Marconato M et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun. 2023 Aug 18;14(1):5032 (2023). doi: 10.1038/s41467-023-40758-0
• Goyal A, Bauer J, Hey J, Papageorgiou DN et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023 Oct 23;14(1):6731 (2023). doi: 10.1038/s41467-023-42417-w.
  
• Nelde A, Schuster H, Heitmann JS et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. . Blood Cancer Dis. 2023 Nov 1;4(6):468-489. doi: 10.1158/2643-3230.BCD-23-0020.
  
• Hoenisch Gravel N, Nelde A, Bauer J et al. TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification. Nat Commun. 2023 Nov 17;14(1):7472.  doi: 10.1038/s41467-023-42692-7.
  

Prof. Dr. Bettina Weigelin
Professorin für Preclinical Imaging of the Immune System
iFIT Beauftragte für Chancengleichheit und Nachwuchsarbeit

bettina.weigelin@med.uni-tuebingen.de

Mehr erfahren

Auswahl von iFIT-bezogenen Publikationen mit dem höchsten Impact Factor.

• Weigelin, B., den Boer, A., Wagena, E. et al. Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nat Comm. Sep 1;12(1):5217 (2021). https://doi.org/10.1038/s41467-021-25282-3 
• Hinterleitner, C., Strähle, J., Malenke, E. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 12, 7005 (2021). https://doi.org/10.1038/s41467-021-27303-7
• Slaats, J., Dieterin, C., Wagena, E. et al. Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery. Cancer Immunol Res. Aug;9(8):926-938. (2021). 10.1158/2326-6066.CIR-20-0741 
• Slaats, J., Wagena, E., Smits, D. et al. Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors. Cancer Immunol Res. Dec 2;10(12):1462-1474. (2022). 10.1158/2326-6066.CIR-22-0113     
• Köhler, D., Leiss, V., Beichert, L. et al. Targeting Gαi2 in neutrophils protects from myocardial ischemia reperfusion injury. Basic Res Cardiol. May 30. (2024). 10.1007/s00395-024-01057-x     
• Bowden, G., Stotz, S., Dunkel, G. et al. [18F] p FBC, a Covalent CLIP-Tag Radiotracer for Detection of Viral Reporter Gene Transfer in the Murine Brain. Bioconjug Chem. Feb 21;35(2):254-264. (2024). 10.1021/acs.bioconjchem.3c00551     
• Scheurer, J., Sauer, B., Focken, J. et al. Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis (2024). 10.1242/dmm.050541        

Dr. Sonal Jaiswal
iFIT  Geschäftsführerin

Sonal.Jaiswal@med.uni-tuebingen.de

Mehr erfahren

Prof. Dr. Helmut Salih
Ärztlicher Direktor der KKE Translationale Immunologie
iFIT Beauftragter für Klinische Translation

helmut.salih@med.uni-tuebingen.de

Mehr erfahren

Auswahl von iFIT-bezogenen Publikationen mit dem höchsten Impact Factor.

• Zekri L, Hagelstein I, Märklin M, Klimovich B, Christie M, Lindner C, Kämereit S, Prakash N, Müller S, Stotz S, Maurer A, Greve C, Schmied B, Atar D, Rammensee HG, Jung G, Salih HR. Immunocytokines with target cell-restricted IL- 15 activity for treatment of B cell malignancies. Sci Transl Med. 2024 Mar 6;16(737):eadh1988. doi:10.1126/scitranslmed.adh1988. Epub 2024 Mar 6. PMID: 38446900.
  
  
• Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M,     Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, Walz JS. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun. 2023 Aug 18;14(1):5032. doi:     10.1038/s41467-023-40758-0. PMID: 37596280; PMCID: PMC10439231.
  
  Heitmann JS, Schlenk RF, Dörfel D, Kayser S, Döhner K, Heuser M, Thol F, Kapp-Schwoerer S, Labrenz J, Edelmann D, Märklin M, Vogel W, Bethge W, Walz JS, Große-Hovest L, Steiner M, Jung G, Salih HR. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023 Aug 17;16(1):96.
  doi: 10.1186/s13045-023-01490-w. PMID: 37587502; PMCID: PMC10433561.
  
  Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, Hoerner S, Hagelstein I, Engel M, Chashchina A, Pfluegler M,  Heitmann JS, Jung G, Salih HR. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023 Apr 5;31(4):1033-1045. doi: 10.1016/j.ymthe.2023.02.010. Epub 2023 Feb 14. PMID: 36793213;
  PMCID: PMC10124076.
  
  Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, Marklin M, Heitmann JS, Kauer J, Osburg L, Zekri L, Bühring HJ, Mueller S, Hörner S, Baeuerle PA, Michaelson JS, Jung G, Salih HR. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022 Mar;10(3):e003882. doi: 10.1136/jitc- 2021-003882. PMID: 35288466;
  PMCID: PMC8921914.